Evaluation of patients’ satisfaction with Angeliq Micro in real clinical practice after 13 cycles of treatment in Russia


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

A decrease in estrogen production during the menopausal transition leads to the appearance of various symptoms that differ in intensity and duration and can have a significant impact on the quality of life. Hot flushes and night sweats are the most common symptoms of the menopause. The most effective treatment for menopausal symptoms is menopausal hormone therapy. Objective: To assess patients’ satisfaction with Angeliq Micro in real clinical practice during 13 cycles of treatment and to evaluate changes in menopausal symptoms and quality of life after 3-4 and 13 cycles of treatment, as well as the reasons for early discontinuation of treatment. Materials and methods: This is a prospective multicenter non-interventional cohort study on the assessment of patients’ satisfaction with Angeliq Micro in real clinical practice. The study included 1570patients aged 50-65 years who experienced moderate or severe vasomotor symptoms and needed treatment with ultra-dose drugs. Results: The patients with moderate to severe intensity of menopausal vasomotor symptoms were satisfied with ultra-dose Angeliq Micro. The proportion of such women exceeded 99% after 13 cycles of treatment. Conclusion: The results of treatment with Angeliq Micro in real clinical practice demonstrate high patients’ satisfaction rate with this method of treatment and provide a modern doctor with more opportunities to help middle-aged women.

Full Text

Restricted Access

About the authors

Svetlana V. Yureneva

Academician V.I. Kulakov National Medical Research Center for Obstetrics, Gynecology and Perinatology, Ministry of Health of Russia

Email: syureneva@gmail.com
Dr. Med. Sci., Leading Researcher, Department of Gynecological Endocrinology

Svetlana V. Prokofieva

North-Western State Medical University named after I.I. Mechnikov, Ministry of Health of Russia

obstetrician-gynecologist of the highest category, ultrasound diagnostics doctor

Natalya V. Spiridonova

Samara State Medical University, Ministry of Health of Russia

Dr. Med. Sci., Professor, Head of the Department of Obstetrics and Gynecology of the Institute of Professional Education

Elena A. Yurasova

Far Eastern State Medical University, Ministry of Health of Russia

Dr. Med. Sci., Professor of the Department of Obstetrics and Gynecology

Lilia M. Ilyina

Association of Gynecologists and Endocrinologists

PhD, Medical adviser on menopaus

References

  1. Юренева С.В., Ермакова Е.И. Менопауза и климактерическое состояние у женщины. Акушерство и гинекология. 2018; 7: 32-8. https://dx.doi.org/10.18565/aig.2018.7.32-38.
  2. Iliodromiti S., Wang W., Lumsden M.A. et al., the International COMMA (Core Outcomes in Menopause) Consortium. Variation in menopausal vasomotor symptoms outcomes in clinical trials: a systematic review. BJOG. 2020; 127: 320-33. https://dx.doi.org/10.1111/1471-0528.15990.
  3. Santoro N., Roeca C., Peters B.A. et al. The Menopause Transition: Signs, Symptoms, and Management Options. J. Clin Endocrinol Metab. 2021;106(1): 1-15. https://dx.doi.org/10.1210/clinem/dgaa764.
  4. Paramsothy P., Harlow S.D., Nan B. et al. Duration of the menopausal transition is longer in women with young age at onset: the multiethnic Study of Women's Health Across the Nation. Menopause. 2017; 24(2): 142-9. https://dx.doi.org/10.1097/GME.0000000000000736.
  5. Col N.F., Guthrie J.R., Politi M., Dennerstein L. Duration of vasomotor symptoms in middle-aged women: a longitudinal study. Menopause. 2009; 16: 453-7. https://dx.doi.org/10.1097/gme.0b013e31818d414e.
  6. Maki P.M., Wu M., Rubin L.H. et al. Hot flashes are associated with altered brain function during a memory task. Menopause. 2020; 27(3): 269-77. https://dx.doi.org/10.1097/GME.0000000000001467.
  7. Dam V., Dobson A.J., Onland-Moret N.C. et al. Vasomotor menopausal symptoms and cardiovascular disease risk in midlife: a longitudinal study. Maturitas. 2020; 133: 32-41. https://dx.doi.org/10.1016/j.maturitas.2019.12.011.
  8. Gray K.E., Katon J.G., LeBlanc E.S. et al. Vasomotor Symptom Characteristics: Are They Risk Factors for Incident Diabetes? Menopause. 2018; 25(5): 520-30. https://dx.doi.org/10.1097/GME.0000000000001033.
  9. Converso D., Viotti S., Sottimano I. et al. The Relationship Between Menopausal Symptoms and Burnout. A Cross-Sectional Study Among Nurses. BMC Women's Health. 2019; 19: 148. https://doi.org/10.1186/s12905-019-0847-6.
  10. Hashimoto K., Yoshida M., Nakamura Y. et al. Relationship between number of menopausal symptoms and work performance in Japanese working women. Menopause. 2021; 28(2): 175-81. https://dx.doi.org/10.1097/ GME.0000000000001698
  11. Organisation for Economic Co-operation and Development OECD. Stat Labour force participation rate, by sex and age group. https://stats.oecd.org
  12. Rees M., Bitze J., Cano A. et al. Global consensus recommendations on menopause in the workplace: A European Menopause and Andropause Society (EMAS) position statement. Maturitas. 2021; 151: 55-62. https://dx.doi.org/10.1016/j.maturitas.2021.06.006.
  13. Stuenkel C.A., Davis S.R., Gompel A. et al. Treatment of Symptoms of the Menopause: An Endocrine Society Clinical Practice Guideline. J. Clin Endocrinol Metab. 2015; 100(11): 3975-4011. https://dx.doi.org/10.1210/jc.2015-2236.
  14. Baber R.J., Panay N., Fenton A., IMS Writing Group. IMS Recommendations on women’s midlife health and menopause hormone therapy. Climacteric. 2016; 19(2): 109-50. https://dx.doi.org/10.3109/13697137.2015.1129166.
  15. Armeni E., Lambrinoudaki I., Ceausu I. et al. Maintaining postreproductive health: A care pathway from the European Menopause and Andropause Society (EMAS). Maturitas. 2016; 89: 63-72. https://dx.doi.org/10.1016/j.maturitas.2016.04.013.
  16. The NAMS 2017 Hormone Therapy Position Statement Advisory Panel. The 2017 hormone therapy position statement of The North American Menopause Society. Menopause. 2017; 24: 728-53. https://dx.doi.org/10.1097/ GME.0000000000000921.
  17. Российское общество акушеров-гинекологов. Клинические рекомендации. Менопауза и климактерическое состояние у женщины. М.; 2021.
  18. Harlow S.D., Gass M., Hall J.E. et al.; STRAW 10 Collaborative Group. Executive summary of the Stages of Reproductive Aging Workshop + 10: addressing the unfinished agenda of staging reproductive aging. Menopause. 2012; 19(4): 387-95. https://dx.doi.org/10.1097/gme.0b013e31824d8f40.
  19. ACOG Practice Bulletin No. 141: management of menopausal symptoms. Obstet Gynecol. 2014; 123: 202-16. https://dx.doi.org/10.1097/01.AOG.0000441353.20693.78.
  20. Gass M.L.S., Maki P., Shifren J.L. et al. NAMS supports judicious use of systemic hormone therapy for women aged 65 years and older. Menopause. 2015; 22(7): 685-6. https://dx.doi.org/10.1097/GME.0000000000000491.
  21. Archer D.F., Schmelter T., Schaefers M. et al. A randomized, double-blind, placebo-controlled study of the lowest effective dose of drospirenone with 17 β-estradiol for moderate to severe vasomotor symptoms in postmenopausal women. Menopause. 2014; 21(3): 227-35. https://dx.doi.org/10.1097/ GME.0b013e31829c1431.
  22. Genazzani A.R., Schmelter T., Schaefers M., Gerlinger C., Gude K. One-year randomized study of the endometrial safety and bleeding pattern of 0.25 mg drospirenone/0.5 mg 17P-estradiol in postmenopausal women. Climacteric. 2013; 16: 490-8. https://dx.doi.org/10.3109/13697137.2013.783797.
  23. Heikinheimo O., Bitzer J., Rodriguez L.G. Real-world research and the role of observational data in the field of gynaecology - a practical review. Eur J. Contracept Reprod Health Care. 2017; 22(4): 250-9. https://dx.doi.org/10.1080/13625187.2017.1361528.
  24. ; ANGEL; OS Report; v 2.0, 26 APR 2021.
  25. Tepper P.G., Brooks M.M., Randolph J.F. Jr et al. Characterizing the trajectories of vasomotor symptoms across the menopausal transition. Menopause. 2016; 23: 1067-74. https://dx.doi.org/10.1097/GME.0000000000000676.
  26. Avis N.E., Crawford S.L., Greendale G. et al. Duration of menopausal vasomotor symptoms over the menopause transition. JAMA Intern Med. 2015; 175: 531-9. https://dx.doi.org/10.1001/jamainternmed.2014.8063.
  27. Moyer A.M., Miller V.M., Faubion S.S. Could personalized management of menopause based on genomics become a reality? Pharmacogenomics. 2016; 17(7): 659-62. https://dx.doi.org/10.2217/pgs.16.17.
  28. Thurston R.C., Carroll J.E., Levine M. et al. Vasomotor symptoms and accelerated epigenetic aging in the Women's Health Initiative (WHI). J. Clin Endocrinol Metab. 2020; 105(4): 1221-7. https://dx.doi.org/10.1210/clinem/dgaa081.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies